CN106344566A - Application of Ternatusine A in preparation of drugs for treating rectal cancer - Google Patents
Application of Ternatusine A in preparation of drugs for treating rectal cancer Download PDFInfo
- Publication number
- CN106344566A CN106344566A CN201610815132.9A CN201610815132A CN106344566A CN 106344566 A CN106344566 A CN 106344566A CN 201610815132 A CN201610815132 A CN 201610815132A CN 106344566 A CN106344566 A CN 106344566A
- Authority
- CN
- China
- Prior art keywords
- ternatusine
- rectal cancer
- drugs
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses application of Ternatusine A in the preparation of drugs for treating rectal cancer and belongs to the technical field of novel applications of drugs. In-vitro MTT antitumor activity evaluation discovers that Ternatusine A also has significant action for human rectal cancer cell lines LOVE1, LOVO, SW620 and SW480; therefore, Ternatusine A is applicable to the preparation of drugs for resisting rectal cancer and has a promising development and application prospect. The application of Ternatusine A related herein in the preparation of drugs for treating rectal cancer is disclosed for the first time, and the inhibitory activity of Ternatusine A for rectal cancer cells is unexpectedly high.
Description
Technical field
The present invention relates to the new application of compound ternatusine a, more particularly, to ternatusine a are in preparation treatment
Application in rectum cancer drug.
Background technology
Cancer is one of disease maximum to human life and health harm, has substantial amounts of people to die from cancer every year.Anticancer
The research and development of medicine are always the focus of study of pharmacy.74% is had to be natural product or derivatives thereof in antitumor drug, such as Ramulus et folium taxi cuspidatae
Alcohol and its derivant are exactly the current clinically reasonable antitumor drug of application effect.Therefore, find from natural product and resist
Chemical compound for treating cancer or lead compound have great importance.
Compound ternatusine a according to the present invention be one deliver within 2013 (zhilai zhan, et al.,
ternatusine a,a new pyrrole derivative with an epoxyoxepino ring from
Ranunculus ternatus.organic letters, 2013,15 (8): 1,970 1973.) noval chemical compound, this compound
Have brand-new framework types, current purposes merely relates to antibacterial, antioxidation and anti AIDS virus, (zhilai zhan, et
al.,ternatusine a,a new pyrrole derivative with an epoxyoxepino ring from
Ranunculus ternatus.organic letters, 2013,15 (8): 1,970 1973.), for according to the present invention
Purposes in preparation treatment rectum cancer drug for the ternatusine a belongs to first public.
Content of the invention
It is an object of the invention to not finding in studying according to existing ternatusine a that it has anti-rectal cancer activity
The present situation of report, there is provided application in preparation medicine for treating rectal cancer for the ternatusine a.
Shown in described compound ternatusine a structure such as formula ():
The present invention is found by external mtt antitumor activity evaluation, and ternatusine a is to people's rectum cancer cell strain
The growth of love1, lovo, sw620 and sw480 also has significant inhibitory action, suppresses the ic50 value point of this 4 plants of cell growths
Not Wei 1.89 ± 0.43 μm, 2.76 ± 0.18m, 1.72 ± 0.38 μm and 2.59 ± 0.31 μm.Therefore, ternatusine a energy
For preparing medicine for treating rectal cancer, there is good development prospect.
Purposes in preparation treatment rectum cancer drug for the ternatusine a according to the present invention is belonged to public first
Open, because framework types belong to brand-new framework types, and it is unexpectedly strong for the inhibitory activity of rectum cancer cell,
There is not the possibility being provided any enlightenment by other compounds, possess prominent substantive distinguishing features, be simultaneously used for the anti-of rectal cancer
Control obviously to have and significantly improve.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to concrete reality
Apply any restriction of example, but be defined in the claims.
Specific embodiment
The preparation method of compound ternatusine a involved in the present invention referring to document (zhilai zhan, et al.,
ternatusine a,a new pyrrole derivative with an epoxyoxepino ring from
ranunculus ternatus.organic letters,2013,15(8):1970–1973.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to concrete reality
Apply any restriction of example, but be defined in the claims.
Embodiment 1: the preparation of compound ternatusine a tablet involved in the present invention:
Take 5 g of compound ternatusine a to add 195 grams of dextrin, mix, conventional tablet presses make 1000.
Embodiment 2: the preparation of compound ternatusine a capsule involved in the present invention:
Take 5 g of compound ternatusine a to add 195 grams of starch, mix, encapsulated make 1000.
To further illustrate its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: the growth inhibition effect to people's rectum cancer cell strain for the compound ternatusine a is evaluated using mtt method
1. method: be in the cell of growth logarithmic (log) phase: people rectum cancer cell strain love1, lovo, sw620 and sw480 (purchase
Buy from Chinese Academy of Sciences's cell bank) with 1.5 × 104Concentration kind is in 96 orifice plates.Original training is sucked after cell culture 24h is adherent
Foster base.Test is divided into blank control group, drug treating group.Blank group changes 1640 culture medium containing 10% hyclone；Medicine
Treatment group is changed and is 100 μm containing concentration, 50 μm, 10 μm, 1 μm, 0.1 μm, 0.01 μm and 0.001 μm of ternatusine a's
Culture medium.After culture 48h, add the mtt of concentration 5mg/ml, continue to be put in co2Incubator cultivates 4h, then along on culture fluid
Portion sucks 100 μ l supernatants, adds 100 μ l dmso, and 10min is placed in dark place, is measured using microplate reader (sunrise Products)
Light absorption value (wavelength 570nm), and cell survival is calculated according to light absorption value, each process sets 6 repeating holes.Cell survival rate
(%)=δ od drug treating/δ od blank × 100.
2. result: ternatusine a has to the growth of people rectum cancer cell strain p love1, lovo, sw620 and sw480
There is significant inhibitory action.This compound suppresses the ic50 of people rectum cancer cell strain love1, lovo, sw620 and sw480 growth
Value be respectively 1.89 ± 0.43 μm, 2.76 ± 0.18m, 1.72 ± 0.38 μm and 2.59 ± 0.31 μm.
Shown by above-described embodiment, the ternatusine a of the present invention to people rectum cancer cell strain love1, lovo,
The growth of sw620 and sw480 has good inhibiting effect.Thus prove, the ternatusine a of the present invention has anti-rectum
Cancer activity, can be used for preparing medicine for treating rectal cancer.
Claims (1)
- Application in treatment rectum cancer drug for the 1.ternatusine a, described compound ternatusine a structure such as formula Shown in ():
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610815132.9A CN106344566A (en) | 2016-09-11 | 2016-09-11 | Application of Ternatusine A in preparation of drugs for treating rectal cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610815132.9A CN106344566A (en) | 2016-09-11 | 2016-09-11 | Application of Ternatusine A in preparation of drugs for treating rectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106344566A true CN106344566A (en) | 2017-01-25 |
Family
ID=57858386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610815132.9A Pending CN106344566A (en) | 2016-09-11 | 2016-09-11 | Application of Ternatusine A in preparation of drugs for treating rectal cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106344566A (en) |
-
2016
- 2016-09-11 CN CN201610815132.9A patent/CN106344566A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106344566A (en) | Application of Ternatusine A in preparation of drugs for treating rectal cancer | |
| CN103251609A (en) | Application of Aspeverin in preparation of medicines for treating tongue cancer | |
| CN103405407B (en) | Application of compound in preparation of medicines for treating pancreatic cancer | |
| CN106309441A (en) | Application of Fistulains A in preparation of drugs for treating cervical cancer | |
| CN106361748A (en) | Application of Ternatusine A in preparation of medicine for treating kidney cancer | |
| CN106344569A (en) | Application of Ternatusine A in preparation of drugs for treating bile duct cancer | |
| CN106389421A (en) | Applications of Ternatusine A in preparing medicines for treating gastric cancer | |
| CN103638016B (en) | Application of Manzamenone O in rectal cancer treatment drugs | |
| CN103432111A (en) | Application of compound to preparation of drug for treating rectal cancer | |
| CN103127091A (en) | Application of Aphanamixoid A in medicines curing colorectal cancer | |
| CN106309439A (en) | Application of Ternatusine A in preparation of medicaments for treating breast cancer | |
| CN103316008A (en) | Application of Aspeverin in preparation of medicine for treating rectal cancer | |
| CN106511338A (en) | Application of Ternatusine A in preparation of drugs for treating tongue cancer | |
| CN103405406B (en) | The application of a kind of compound in preparation treatment endometrial cancer drug | |
| CN106309453A (en) | Application of Friedolanostanes in manufacture of medicaments for treating rectal cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872138B (en) | Application of Houttuynoid C in drug for treating colorectal cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872117B (en) | Application of Houttuynoid D in preparing medicine for treating gastric cancer | |
| CN103655552A (en) | Application of Manzamenone O in pancreas cancer treatment medicines | |
| CN105232553A (en) | Application of Hystrolinone in preparing medicine for treating rectal carcinoma | |
| CN106389423A (en) | Application of Ternatusine A in preparing medicines for treating endometrial cancer | |
| CN106265652A (en) | Ternatusine A application in preparation treatment pancreatic cancer drug | |
| CN106491618A (en) | Applications of the Friedolanostanes in treatment laryngeal cancer medicine is prepared | |
| CN105287517A (en) | Use of Pyrrospirone B in preparation of drug for treating rectal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170125 |
|
| WD01 | Invention patent application deemed withdrawn after publication |